PDCD1 and metastatic melanoma: Articles were included if they examined the treatment of intracranial metastatic melanoma with SRS and BRAFi/MEKi inhibitors or immunotherapeutic checkpoint inhibitors (i.e., anti-PD1 and anti-CTLA4 monoclonal antibodies).